Corona Remedies Ltd — Q4 FY26
Corona Remedies delivered a strong FY26, with revenue of ₹1,403 Cr (+17.3% YoY) and PAT of ₹199 Cr (+33.4% YoY), exceeding guided ranges.
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY26
Revenue growth of 15% for FY26
Management reiterated annual guidance of 15% revenue growth, with 9M already at ~16%.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY26
PAT growth of 20% for FY26
Profit after tax growth target of 20% for the full year, with 9M PAT growth at 31%.
Delayed
The current-quarter record did not contain enough evidence of delivery; the item remains delayed for follow-up.
heuristic_v1
Q3 FY26
Launch of GLP-1 injectable in March 2026
Plan to launch GLP-1 injectable (brand Wing Tide) on patent expiry day in March 2026.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1